Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Barinthus Biotherapeutics (BRNS) Receivables - Other (2020 - 2026)

Barinthus Biotherapeutics filings provide 7 years of Receivables - Other readings, the most recent being $1.2 million for Q1 2026.

  • On a quarterly basis, Receivables - Other fell 58.89% to $1.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.2 million, a 58.89% decrease, with the full-year FY2025 number at $1.1 million, down 84.48% from a year prior.
  • Receivables - Other hit $1.2 million in Q1 2026 for Barinthus Biotherapeutics, up from $1.1 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $17.0 million in Q2 2022 to a low of $154000.0 in Q1 2022.
  • Median Receivables - Other over the past 5 years was $4.5 million (2024), compared with a mean of $4.3 million.
  • Biggest five-year swings in Receivables - Other: crashed 98.24% in 2023 and later soared 1407.67% in 2024.
  • Barinthus Biotherapeutics' Receivables - Other stood at $4.5 million in 2022, then increased by 8.08% to $4.9 million in 2023, then soared by 45.46% to $7.1 million in 2024, then plummeted by 84.48% to $1.1 million in 2025, then increased by 11.19% to $1.2 million in 2026.
  • The last three reported values for Receivables - Other were $1.2 million (Q1 2026), $1.1 million (Q4 2025), and $4.6 million (Q3 2025) per Business Quant data.